Medication info

CDSCC Solution

Prescription medicationInjection
Ingredient · strength
Sodium Chloride›Strength being verifiedMagnesium Chloride Hydrate›Strength being verifiedCalcium Chloride Hydrate›Strength being verifiedPotassium Chloride›Strength being verifiedGlucose›Strength being verifiedCitric Acid Hydrate›Strength being verified
Manufacturer / importer
Palmgen Science Co., Ltd.
Appearance
1 box contains 6 types (8 pieces) of bags, with each bag characterized as follows: - Colorless or white powder packaged in polyethylene film bags of gray (Sodium Chloride) - 3 bags - Blue (Chloride)
Packaging
28.012 kg
Approval status
Active

MFDS item code 201604150 · Notified 2016.07.04 · Insurance code 670104051

Summary

Main use
Hemodialysis treatment in patients with chronic renal failure
Who receives it
Adults
Adult administration
1. Dilute this medicine using dialysis-grade dilution water (hereinafter, dilution water) as follows. 1) Place 60∼72L of dilution water in a suitable mixing container. 2) Slowly add 1 packet of the yellow bag (citric acid hydrate) to the container with dilution water and mix well. 3) Add all of the following to the mixing container: 3 packets of the gray bag (sodium chloride), 1 packet of the blue bag (magnesium chloride), 1 packet of the red bag (calcium chloride), 1 packet of the brown bag (potassium chloride), and 1 packet of the green bag (glucose). 4) Add more dilution water to bring the total solution volume to 100L. 5) Stir thoroughly until all powder has completely dissolved. 2. Use as dialysate for hemodialysis using a bicarbonate dialysate supply system at a dilution ratio of (1 part diluted solution of this medicine : 1.26 parts 7% sodium bicarbonate dialysis solution : 32.74 parts dilution water). 3. The amount depends on the duration of dialysis; use 150~300L as dialysate. *Electrolyte concentrations in the solution after dilution (unit: mEq/L) Na+ K+ Ca2+ Mg2+ Cl- Citrate3- HCO3- 140 2.0 2.5 1.0 114.0 2.0 30 *Glucose: 1g/L

Ingredients

Manufacturer
Palmgen Science Co., Ltd.

Efficacy & effects

Hemodialysis treatment in patients with chronic renal failure

View approved original text

For patients with chronic renal failure, the dialysis solution is used to remove waste products accumulated in the body due to kidney function decline and to maintain electrolyte balance. The dialysis solution acts to purify the blood, helping to improve the patient's physical condition. This supports the effective elimination of excess fluids and waste from the body and prevents complications caused by electrolyte imbalances. Such dialysis solutions are crucial in the treatment of chronic renal failure, significantly contributing to the maintenance of the patient's health and the improvement of their quality of life.

How it is given

Adult administration

1. Dilute this medicine using dialysis-grade dilution water (hereinafter, dilution water) as follows. 1) Place 60∼72L of dilution water in a suitable mixing container. 2) Slowly add 1 packet of the yellow bag (citric acid hydrate) to the container with dilution water and mix well. 3) Add all of the following to the mixing container: 3 packets of the gray bag (sodium chloride), 1 packet of the blue bag (magnesium chloride), 1 packet of the red bag (calcium chloride), 1 packet of the brown bag (potassium chloride), and 1 packet of the green bag (glucose). 4) Add more dilution water to bring the total solution volume to 100L. 5) Stir thoroughly until all powder has completely dissolved. 2. Use as dialysate for hemodialysis using a bicarbonate dialysate supply system at a dilution ratio of (1 part diluted solution of this medicine : 1.26 parts 7% sodium bicarbonate dialysis solution : 32.74 parts dilution water). 3. The amount depends on the duration of dialysis; use 150~300L as dialysate. *Electrolyte concentrations in the solution after dilution (unit: mEq/L) Na+ K+ Ca2+ Mg2+ Cl- Citrate3- HCO3- 140 2.0 2.5 1.0 114.0 2.0 30 *Glucose: 1g/L

Precautions

This drug should be used with caution in patients taking digitalis glycosides because low serum potassium may result in digitalis toxicity. During or after dialysis, hypoglycemic symptoms may occur due to low blood sugar, so if such symptoms appear, intravenous glucose should be administered or sugar intake should be supplemented immediately. Conversely, hyperglycemia may also occur, in which case dialysis should be done using a solution without glucose. The use of this medication may increase thirst, leading to excessive fluid intake, which can result in increased weight or elevated blood pressure. In such cases, ultrafiltration pressure should be adjusted to manage body fluids or weight. After or during dialysis, blood calcium levels may drop, leading to cramps or discomfort. In these cases, it may be necessary to switch to a dialysis solution with high calcium concentration or administer calcium supplements. Bone-related complications such as osteoporosis, osteomalacia, and fibrous osteitis may occur, requiring treatment such as the administration of active vitamin D3 preparations. Additionally, ectopic calcification may arise, necessitating the management of serum phosphate levels with phosphate binders to maintain them within the normal range. Dialysis disequilibrium syndrome may occur, presenting symptoms like headache, nausea, vomiting, cramps, and altered consciousness; in such cases, measures to reduce dialysis efficiency may be necessary. This drug can affect the cardiovascular system, with low blood pressure or shock symptoms possibly emerging, in which case dialysis may need to be stopped or the efficiency lowered, and appropriate treatment such as intravenous fluids or blood pressure-raising agents administered. Although rare, blood pressure may rise, necessitating the administration of antihypertensives or changes in dialysis solution. This drug is used for hemodialysis in patients with chronic renal failure, particularly when high acetate dialysis solutions are ineffective for metabolic acidosis or when side effects such as low blood pressure or disequilibrium syndrome occur. It is also used when glucose control is difficult, employing solutions containing glucose. It is utilized to treat solutions with low potassium, calcium, and magnesium concentrations when hyperkalemia or hypermagnesemia is not improved. Care should be taken as high calcium levels may cause hypercalcemia. Regular blood tests to check electrolytes, acid-base balance, blood sugar levels, etc., are essential. During or after dialysis, monitoring changes in serum citric acid, calcium levels, oxygen, and carbon dioxide concentrations is crucial. Pregnant women or those who may become pregnant should only use this drug when the benefits of treatment outweigh the potential risks, as its safety has not been established. Safety in pediatric patients has also not been established, so it should be used with caution. Elderly patients may experience bone complications, thus appropriate management with regular clinical examinations and administration of active vitamin D3 preparations is recommended. Patients with aluminum bone disease should be monitored for bone density, and high calcium dialysis solutions should be employed as necessary. Dialysis water for preparation should strictly meet specified standards, and attention should be given to the risk of bleeding due to anticoagulant use or membrane damage. During preparation, use electrolyte solutions for artificial kidney dialysis and sodium bicarbonate solutions carefully; they should not be used alone, but properly diluted as prescribed. If concentrations are too high or low, symptoms such as headache, palpitations, changes in blood pressure, and altered consciousness may occur. Check the electrolyte concentrations, osmotic pressure, pH of the dialysis solution, and use it immediately afterward, never storing for longer than 2 hours. Do not use if insoluble substances are detected. The dialysis solution should be warmed to body temperature prior to use and is not meant for injections or peritoneal dialysis. It is crucial to closely monitor the patient's condition while using this drug, taking appropriate action as necessary.

Side effects

  • Hypoglycemia
  • hyperglycemia
  • weight gain
  • increased blood pressure
  • seizures due to hypocalcemia
  • discomfort
  • osteoporosis
  • osteomalacia
  • fibrous osteitis
  • heterotopic calcification
Show 19 more
  • headache
  • nausea
  • vomiting
  • seizures
  • altered consciousness
  • discomfort
  • malaise
  • hypotension
  • shock
  • increased blood pressure
  • headache
  • palpitations
  • increased blood pressure
  • altered consciousness
  • limb numbness
  • systemic malaise
  • chest discomfort
  • rapid decrease in blood pressure
  • altered consciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to protect it from air or moisture, ideally at room temperature between 1°C and 30°C. Maintaining the proper temperature and container conditions will help ensure the medication's effectiveness safely.

Appearance and packaging

Appearance

1 box contains 6 types (8 pieces) of bags, with each bag characterized as follows: - Colorless or white powder packaged in polyethylene film bags of gray (Sodium Chloride) - 3 bags - Blue (Chloride)

Package unit

28.012 kg

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.